Skip to main content
Barry Feinberg, MD, Anesthesiology, Saint Louis, MO, SSM Health St. Joseph - St. Charles

BarryIFeinbergMD

Anesthesiology Saint Louis, MO

Pain Medicine

Physician

Dr. Feinberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Feinberg's full profile

Already have an account?

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Anesthesiology, 1981 - 1984
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Anesthesiology, 1980 - 1984
  • Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital
    Zucker School of Medicine at Hofstra/Northwell at Staten Island University HospitalInternship, Internal Medicine, 1980 - 1981
  • State University of New York Downstate Medical Center College of Medicine
    State University of New York Downstate Medical Center College of MedicineClass of 1980

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1992 - 2026
  • MO State Medical License
    MO State Medical License 1986 - 2025
  • CO State Medical License
    CO State Medical License 2017 - 2025
  • PA State Medical License
    PA State Medical License 1982 - 1986
  • American Board of Anesthesiology Anesthesiology
  • American Board of Anesthesiology Pain Medicine

Publications & Presentations

PubMed

Press Mentions

  • Janssen Announces Erdafitinib Improved Overall Survival Versus Chemotherapy in Patients with Metastatic or Unresectable Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations After Prior Anti-PD-(L)1 Treatment
    Janssen Announces Erdafitinib Improved Overall Survival Versus Chemotherapy in Patients with Metastatic or Unresectable Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations After Prior Anti-PD-(L)1 TreatmentJune 10th, 2023

Hospital Affiliations